Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy
Read More Pharma Industry News Why Hemispherian’s FDA-cleared GLIX1 trial could be a turning point for brain cancer therapy Hemispherian gets FDA clearance for GLIX1 Phase 1 trial in glioblastoma. Find out how this novel therapy targets DNA repair to combat deadly brain tumors. byPallavi MadhirajuAugust 5, 2025